Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3)

JY Huang; TL Larose; HN Luu; R Wang; A Fanidi; K Alcala; VL Stevens; SJ Weinstein; D Albanes; NE Caporaso; MP Purdue; RG Ziegler; ND Freedman; Q Lan; RL Prentice; M Pettinger; CA Thomson; Q Cai; J Wu; WJ Blot; XO Shu; W Zheng; AA Arslan; A Zeleniuch-Jacquotte; L Le Marchand; LR Wilkens; CA Haiman; X Zhang; MJ Stampfer; J Han; GG Giles; AM Hodge; G Severi; M Johansson; K Grankvist; A Langhammer; K Hveem; YB Xiang; HL Li; YT Gao; K Visvanathan; PM Ueland; Ø Midttun; A Ulvi; JE Buring; IM Lee; HD Sesso; JM Gaziano; J Manjer; C Relton; WP Koh; P Brennan; M Johansson; JM Yuan

Journal article

Circulating markers of cellular immune activation in prediagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3)

JY Huang, TL Larose, HN Luu, R Wang, A Fanidi, K Alcala, VL Stevens, SJ Weinstein, D Albanes, NE Caporaso, MP Purdue, RG Ziegler, ND Freedman, Q Lan, RL Prentice, M Pettinger, CA Thomson, Q Cai, J Wu, WJ Blot Show all

International Journal of Cancer | WILEY | Published : 2020

DOI: 10.1002/ijc.32555

Download PDF

Abstract

Cell-mediated immune suppression may play an important role in lung carcinogenesis. We investigated the associations for circulating levels of tryptophan, kynurenine, kynurenine:tryptophan ratio (KTR), quinolinic acid (QA) and neopterin as markers of immune regulation and inflammation with lung cancer risk in 5,364 smoking-matched case–control pairs from 20 prospective cohorts included in the international Lung Cancer Cohort Consortium. All biomarkers were quantified by mass spectrometry-based methods in serum/plasma samples collected on average 6 years before lung cancer diagnosis. Odds ratios (ORs) and 95% confidence intervals (CIs) for lung cancer associated with individual biomarkers wer..

View full abstract

University of Melbourne Researchers

Graham Giles Author

Allison Hodge Author

Related Projects (3)

Epidemiology of chronic disease, health interventions and DNA studies

THE HEALTH 2020 COHORT STUDY (HEALTH 2020)

Our aim is to develop appropriate infrastructures necessary to facilitate access by researchers to the accumulated data, including questionn..

PRECISION PUBLIC HEALTH FOR MAJOR CANCERS - NOVEL APPROACHES TO BUILDING THE GENETIC, EPIGENETIC AND LIFESTYLE KNOWLEDGE BASE FOR ASSESSING RISK AND PROGNOSIS

The Program of research seeks to increase our understanding of cancer risk. We will use our large collections of population and family-based..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

Grant sponsor: National Cancer Institute; Grant numbers: P01CA87969, P30CA016087, R01CA092447, R01CA144034, U01CA155340, U01CA202979, UM1CA167552, UM1CA173640, UM1CA182876, UM1CA182910, UM1CA182934, UM1CA186107; Grant sponsor: National Institutes of Health; Grant numbers: CA047988, CA097193, CA182913, CA34944, CA40360, HL043851, HL080467, HL099355, HL26490, HL34595, P30ES000260; Grant sponsor: U.S. Department of Health and Human Services; Grant numbers: HHSN261201500005C, HHSN268201100046C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C, HHSN271201600004C; Grant sponsor: VicHealth and Cancer Council Victoria and Australian National Health and Medical Research Council; Grant numbers: 1074383, 209057, 396414